Nanotechnology in the Treatment of Skin Disorders Such as Psoriasis

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin condition that markedly impacts patients' quality of life and presents difficulties for efficient therapy because to inadequate medication penetration, systemic adverse effects, and restricted therapeutic retention.  Traditional treatments, such as topical corticosteroids, systemic medications, and phototherapy, often demonstrate inadequate effectiveness and side effects, prompting the investigation of innovative drug delivery methods.  Nanotechnology has emerged as a viable methodology in dermatology, providing nanoscale drug delivery systems including liposomes, niosomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, nanoemulsions, dendrimers, and metallic nanoparticles.  Pre-clinical studies utilizing murine and rodent models of psoriasis have shown that these nanocarrier systems improve skin penetration, facilitate controlled and sustained drug release, enhance the stability of therapeutic agents, and modulate inflammatory and oxidative pathways, leading to superior lesion healing, diminished epidermal hyperplasia, and reduced cytokine expression relative to conventional treatments.  Notwithstanding their potential effectiveness, issues such as intricate synthesis, possible immunogenicity, unpredictability in drug loading, and insufficient long-term safety evidence must be resolved to guarantee their use in clinical practice.  Nanotechnology-based formulations provide a revolutionary and precise approach to pre-clinical psoriasis care, offering insights into the creation of safer, more effective, and patient-centric medications.